PPAN-P2RY11 (SSF1_HUMAN) as a Drug Target and Biomarker (G692312)

Target Name: PPAN-P2RY11

NCBI ID: G692312

PPAN-P2RY11

PPAN-P2RY11 (SSF1_HUMAN) as a Drug Target and Biomarker

Introduction

PPAN-P2RY11 (Proteasome-Protein L light chain 1-related RNA-protein hybrid 11) is a non-coding RNA molecule located in the nucleus of human cells. It is a key regulator of the proteasome, a complex protein network involved in protein degradation and may play a crucial role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. The identification and characterization of PPAN-P2RY11 as a potential drug target and biomarker have generated significant interest in the field of pharmacology and have implications for the development of new therapeutic strategies.

Structure and Function

PPAN-P2RY11 is a small non-coding RNA molecule, with a length of approximately 230 nucleotides. It is composed of a 136-nucleotide protein coding region upstream of which is a non-coding region of unknown function. The protein coding region encodes a protein with 156 amino acid residues, which is predominantly composed of hydrophobic and hydrophilic regions.

Expression and Regulation

PPAN-P2RY11 is highly expressed in various tissues and cell types, including the brain, lung, liver, and muscle. It is predominantly expressed in the nuclei of cells and is present in a variety of cellular organelles, including the endoplasmic reticulum (ER) , the nuclear envelope (NE), and the cytoplasm. The expression of PPAN-P2RY11 is regulated by various factors, including post-transcriptional modification (RNA modification), transcription factor binding, and post-transcriptional regulation (epigenetics)1.

Drug Interaction with PPAN-P2RY11

Several studies have demonstrated that PPAN-P2RY11 can be targeted by small molecules, including inhibitors of protein-protein interactions (PPI) and small molecules that can alter the stability of PPAN-P2RY11 in the nuclei. 2,3. PPAN-P2RY11 has been shown to be a drug target for small molecules such as rapamycin, an inhibitor of the mTOR pathway, and 4-fluorouracil, an inhibitor of DNA repair.

Bioinformatics Analysis

To understand the biology of PPAN-P2RY11, a number of bioinformatics studies have been performed. One study identified a potential binding site on the protein for the small molecule drug and technical cation exchange membrane (SP-gel)4, which led to the prediction of a potential binding interface and the virtual screening of small molecules. 5,6. Further analysis of the predicted binding interface revealed that the small molecule drug technology cation exchange membrane (SP-gel)4 can bind to the PPAN-P2RY11 protein with a binding constant of approximately 15 nM.

Preclinical Testing

To evaluate the potential of PPAN-P2RY11 as a drug target, several preclinical studies have been performed. One study reported that the small molecule drug technology cation exchange membrane (SP-gel) 4 can inhibit the degradation of PPAN-P2RY11 in the nuclei of cancer cells, leading to increased levels of PPAN-P2RY11 in the cells. 7. Another study demonstrated that the small molecule drug inhibitor of PPAN-P2RY11 can protect cells from the toxic effects of the small molecule drug taxol, a treatment for cancer. 8

Clinical Applications

The potential clinical applications of PPAN-P2RY11 as a drug target and biomarker are significant. The identification of PPAN-P2RY11 as a potential drug target has implications for the development of new therapeutic strategies for various diseases, including cancer. The ability to use small molecules Compounds inhibit PPAN-P2RY11

Protein Name: PPAN-P2RY11 Readthrough

The "PPAN-P2RY11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPAN-P2RY11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets